Linhui Wang
Senior Director, Preclinical Research Vaccine @ Abogen Biosciences
About
Extensive experience in preclinical screening studies and CMC studies of both inactivated and mRNA vaccines: 1. Take a lead role in the CMC development of an inactivated COVID-19 vaccine, IND approved after 16 rounds of pre-IND meetings with CDE, developed and validated antibody detection methods for phase I-II clinical trials and transferred to National Institutes for Food and Drug Control (NIFDC). 2. Take a lead role in quality control (release and characterization tests) for the preclinical development of a lyophilized serum-free rabies vaccine, now in NDA application phase. 3. Broad experience in both viral and bacterial vaccines development. 4. As the project leader, secured internal CMC approval for a viral mRNA vaccine project, CMC and GLP safety studies completed. Set-up and monitoring an early-stage therapeutic viral mRNA vaccine project and two bacterial mRNA vaccine projects.
China
Suzhou
Pharmaceuticals
Investigational New Drug Application (IND), Chemistry, Manufacturing, and Controls (CMC), Analytical Method Validation, Molecular Biology, Antibodies, Animal Models, Infectious Diseases, Vaccines, Immunology, Cell, Cell Culture, Cancer Research, Biochemistry, Western Blotting, Flow Cytometry, PCR, ELISA, Cell Biology, Molecular Cloning, In Vitro
Experience
Senior Director, Preclinical Research Vaccine
Abogen Biosciences
Director, Preclinical Research Vaccine
Abogen Biosciences
Suzhou
Associate Director （CMC co-leader of inactivated rabies vaccine, approved for III clinical trial)
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Ningbo, Zhejiang, China
CMC co-leader of inactivated COVID-19 vaccine (Vero cell) (I/II clinical trials completed)
AIM vaccine group
Ningbo
Principal Investigator of Quadrivalent Influenza Vaccine (MDCK cell) Project
Aimei Hissen Vaccine (Dalian) Co., Ltd.
Associate Director of R&D Center
Aimei Hissen Vaccine (Dalian) Co., Ltd.
Co-project manager of the collaborative project between Hissen and Imperial College London
Aimei Hissen Vaccine (Dalian) Co., Ltd.
Dalian, Liaoning, China
Project name: Future Vaccine Manufacturing Research (FVMR) Hub: Advancing the manufacture and deployment of cost effective vaccines —— Work Stream 5 —— Re-engineering next generation yeast platforms. PI: Prof. Robin Shattock Work stream leader: Prof. Xiaoning Xu Operations Director: Dr. Sudeshkumar S. Kothari My working subjects: contract and agreement affairs, fainance, meeting and Tel-con, material transfer, oral translation.
Project Manager of Bacterial Vaccine and Bacteriophage Lab
Aimei Hissen Vaccine (Dalian) Co., Ltd.
Dalian, Liaoning, China
1. Establish a lab for bacterial vaccine and bacteriophage research. Be responsible for pre-order test, purchase and maintenance of instruments including bioreactors. 2. Manage a lab of 5 employee for experiment design, data interpret and protocol writing 3. Establish a pilot scale fermentation and purification strategy for bacteriophages of S. aureus and P. aeruginosa. Scale up expression and purification of recombinant bacteriophage lysins. 4. Set up quality control parameters for bacteriophage, including complete genome sequencing of bacteriophage seeds and the bacterial host, test set up and validation the tests for host proteins, host DNA and endotoxin 5. Evaluate the efficacy of bacteriophage in mouse burn wound infection model 6. Engaged in contact with collaborators for project issues, GLP labs for safety study, and NIFDC for consultation of regulation affairs 7. Write up grant applications and reports
Post-doc fellow
Dalian Hissen Bio-pharm. Co., Ltd.
Dalian, Liaoning, China
1. Display S. aureus antigen epitope on the surface of bacteriophage M13 or T7, or whole antigen molecule on the surface of yeast. 2. Characterize the antibody response and T helper cell phenotype (Th1/Th2/Th17) of displayed vaccine in mice.
Associate in Medicine
Harvard Medical School
181 Longwood ave, Boston, 02115
1. Evaluate protective efficacy of genetically conjugated S. aureus vaccine (CP5-Hla and CP8-Epa, developed by GlycoVaxyn AG) in rodent models of catheter associated endocarditis (passive immunization only), pneumonia and bacteremia. 2. Evaluate in vitro function of IgG raised by CP5-Hla vaccine with ELISA, opsonic killing assay (OPK) and toxin neutralization assay. 3. Investigate the role of T cell in the protection of CP5-Hla against S. aureus pneumonia by CD4+ or CD8+ T cell depletion 4. Mentor a summer student to make an Atl and TagO double mutant of S. aureus by phage transduction 5. Write up standard lab protocols for OPK assay, endocarditis and pneumonia models
Education
Harvard Medical School
Evaluation the efficacy of S. aureus bioconjugate vaccine
Dalian University of Technology
Bioconjugated S. aureus vaccine
1. Characterize egg yolk antibody (IgY) specific for the most prevalent serotypes (CP5, CP8 and CP-) S. aureus responsible for bovine mastitis. 2. Evaluate protective efficacy of IgY against S. aureus total exo-proteins on bovine mammary epithelial cell (MAC-T) and bovine polymorphonuclear neutrophil (PMN) 3. Evaluate the efficacy of a combination of toxin and capsule specific IgY for the treatment of clinical bovine mastitis. 4. Evaluate the therapeutic effect of a bacteriophage of Klebsiella pneumoniae for the treatment of lethal pneumonia in mice
Linhui Wang's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.